GlassScriptPhysician profile
Thu A Hoang
NPI 1801821699
$2,248.00
in general payments reported to CMS, 2019-2025
29 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $608 · 2021: $263 · 2022: $341 · 2023: $101 · 2024: $360 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $468.03 | 2019-2025 | Airsupra |
| Novo Nordisk INC | $390.59 | 2019-2021 | |
| Lilly USA, LLC | $263.98 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $129.23 | 2021-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $118.15 | 2019-2024 | Veozah |
| Amarin Pharma, INC. | $99.00 | 2019-2022 | |
| Amgen INC. | $97.13 | 2019-2021 | |
| Qol Medical, LLC | $71.74 | 2024-2025 | Sucraid, Sucraid |
| Allergan, INC. | $52.59 | 2020 | |
| Exact Sciences Corporation | $48.63 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.96 | 2021-2022 | |
| Dexcom, INC. | $35.76 | 2021 | |
| Glaxosmithkline, LLC. | $35.23 | 2022-2023 | Trelegy Ellipta |
| Abbvie INC. | $33.70 | 2021-2022 | |
| Scynexis, INC. | $33.25 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $32.00 | 2024 | |
| Paratek Pharmaceuticals, INC. | $31.75 | 2021-2025 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $29.23 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $29.11 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $28.78 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.05 | 2022-2024 | Zoryve |
| Pfizer INC. | $24.22 | 2024 | |
| Acella Pharmaceuticals, LLC | $20.10 | 2024 | NP Thyroid 60 |
| Esperion Therapeutics, INC. | $19.70 | 2020 | |
| Merck Sharp & Dohme LLC | $19.40 | 2022 | |
| Eisai INC. | $18.15 | 2022 | |
| Boston Scientific Corporation | $18.13 | 2025 | Wavewriter Alpha Prime 16 |
| Supernus Pharmaceuticals, INC. | $14.85 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thu Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.